These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34497808)

  • 1. PARP1 Inhibitor Combined With Oxaliplatin Efficiently Suppresses Oxaliplatin Resistance in Gastric Cancer-Derived Organoids via Homologous Recombination and the Base Excision Repair Pathway.
    Li H; Wang C; Lan L; Wu W; Evans I; Ruiz EJ; Yan L; Zhou Z; Oliveira JM; Reis RL; Hu Z; Chen W; Behrens A; He Y; Zhang C
    Front Cell Dev Biol; 2021; 9():719192. PubMed ID: 34497808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance.
    Harada K; Sakamoto N; Ukai S; Yamamoto Y; Pham QT; Taniyama D; Honma R; Maruyama R; Takashima T; Ota H; Takemoto Y; Tanabe K; Ohdan H; Yasui W
    Gastric Cancer; 2021 Nov; 24(6):1264-1277. PubMed ID: 34272617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin.
    Arena S; Corti G; Durinikova E; Montone M; Reilly NM; Russo M; Lorenzato A; Arcella P; Lazzari L; Rospo G; Pagani M; Cancelliere C; Negrino C; Isella C; Bartolini A; Cassingena A; Amatu A; Mauri G; Sartore-Bianchi A; Mittica G; Medico E; Marsoni S; Linnebacher M; Abrignani S; Siena S; Di Nicolantonio F; Bardelli A
    Clin Cancer Res; 2020 Mar; 26(6):1372-1384. PubMed ID: 31831554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of oxaliplatin and β-carotene suppresses colorectal cancer by regulating cell cycle, apoptosis, and cancer stemness
    Lee J; Heo SC; Kim Y
    Nutr Res Pract; 2024 Feb; 18(1):62-77. PubMed ID: 38352212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined olaparib and oxaliplatin inhibits tumor proliferation and induces G2/M arrest and γ-H2AX foci formation in colorectal cancer.
    Xu K; Chen Z; Cui Y; Qin C; He Y; Song X
    Onco Targets Ther; 2015; 8():3047-54. PubMed ID: 26543375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. METTL3 promotes drug resistance to oxaliplatin in gastric cancer cells through DNA repair pathway.
    Wang Y; Hong Z; Song J; Zhong P; Lin L
    Front Pharmacol; 2023; 14():1257410. PubMed ID: 37822880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer.
    Lai J; Yang H; Zhu Y; Ruan M; Huang Y; Zhang Q
    BMC Cancer; 2019 Jun; 19(1):602. PubMed ID: 31215481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Antitumor Effect of TPD52L2 Silencing on Oxaliplatin-Resistant Gastric Carcinoma Is Related to Endoplasmic Reticulum Stress
    Zhang Y; Yang D; Wei Z; Zhang X; Hu Z; Fu H; Xu J; Wang W
    Evid Based Complement Alternat Med; 2022; 2022():4451178. PubMed ID: 35087592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells.
    Plasencia C; Martínez-Balibrea E; Martinez-Cardús A; Quinn DI; Abad A; Neamati N
    Int J Oncol; 2006 Jul; 29(1):225-35. PubMed ID: 16773204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
    Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
    J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin and Gedatolisib (PKI-587) Co-Loaded Hollow Polydopamine Nano-Shells with Simultaneous Upstream and Downstream Action to Re-Sensitize Drugs-Resistant Hepatocellular Carcinoma to Chemotherapy.
    Zhang YC; Wu CG; Li AM; Liang Y; Ma D; Tang XL
    J Biomed Nanotechnol; 2021 Jan; 17(1):18-36. PubMed ID: 33653494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells.
    Gomez MK; Illuzzi G; Colomer C; Churchman M; Hollis RL; O'Connor MJ; Gourley C; Leo E; Melton DW
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32526907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MLN4924 suppresses the BRCA1 complex and synergizes with PARP inhibition in NSCLC cells.
    Guo ZP; Hu YC; Xie Y; Jin F; Song ZQ; Liu XD; Ma T; Zhou PK
    Biochem Biophys Res Commun; 2017 Jan; 483(1):223-229. PubMed ID: 28034751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiproliferative Activity of Krukovine by Regulating Transmembrane Protein 139 (TMEM139) in Oxaliplatin-Resistant Pancreatic Cancer Cells.
    Lee JH; Lee SH; Lee SK; Choi JH; Lim S; Kim MS; Lee KM; Lee MW; Ku JL; Kim DH; Cho IR; Paik WH; Ryu JK; Kim YT
    Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway.
    Yin J; Wang L; Wang Y; Shen H; Wang X; Wu L
    Onco Targets Ther; 2019; 12():3893-3903. PubMed ID: 31190888
    [No Abstract]   [Full Text] [Related]  

  • 16. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
    Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway.
    Ruiz de Porras V; Bystrup S; Martínez-Cardús A; Pluvinet R; Sumoy L; Howells L; James MI; Iwuji C; Manzano JL; Layos L; Bugés C; Abad A; Martínez-Balibrea E
    Sci Rep; 2016 Apr; 6():24675. PubMed ID: 27091625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property.
    Prasad CB; Prasad SB; Yadav SS; Pandey LK; Singh S; Pradhan S; Narayan G
    Sci Rep; 2017 Oct; 7(1):12876. PubMed ID: 28993682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long non-coding RNA DDX11-AS1 facilitates cell progression and oxaliplatin resistance via regulating miR-326/IRS1 axis in gastric cancer.
    Song W; Qian Y; Zhang MH; Wang H; Wen X; Yang XZ; Dai WJ
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3049-3061. PubMed ID: 32271422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.